Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.
|Translated title of the contribution||具表皮細胞生長因子接受器突變之肺麟狀細胞癌病患使用上皮細胞生長因子接收器－酪胺酸酶抑制劑呈顯著治療效果：病例報告|
|Number of pages||7|
|Publication status||Published - 2015|
- epidermal growth factor receptor (EGFR) mutation
- EGFR tyrosine kinase inhibitor (TKI)
- pulmonary squamous cell carcinoma
Lee, K-L., Lin, S-E., Chung, C-C., Hsiao, S-H., & Chung, C-L. (2015). Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report. 胸腔醫學, 30(3), 157-163. http://www.AiritiLibrary.com/Publication/Index/10239855-201506-201505290009-201505290009-157-163